SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
Pharm Country
Mad Money’s Jim Cramer Wants Johnson & Johnson Busted Into Three Companies
July 21, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Johnson & Johnson HIV Vaccine Blocks Virus in 50% of Monkeys, Soon to Start Human Trial in 400
July 6, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Johnson & Johnson, Roche Allegedly Circle GlaxoSmithKline as Takeover Speculation Intensifies
June 16, 2015
 · 
4 min read
Biotech Bay
Johnson & Johnson And The 9 Other Stocks Baby Boomers Love Most
June 1, 2015
 · 
1 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
Johnson & Johnson Announced 10 New Approval Applications with $1 Billion Revenue Potential Each
May 20, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Achillion, Johnson & Johnson Hammer Out $1 Billion+ Hep C R&D Pact to Compete With Gilead and AbbVie
May 19, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
BioCapital
New FDA Warning Impacts Diabetes Drugs Made by AstraZeneca PLC, Johnson & Johnson and Eli Lilly
May 18, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
AbbVie, Johnson & Johnson Floated as Possible Suitors For Freshly Flush Galapagos
May 14, 2015
 · 
3 min read
Biotech Bay
Johnson & Johnson’s Piping Hot Pipeline
May 13, 2015
 · 
1 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
December 29, 2025
 · 
5 min read
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Load More